CN113332215A - 一种治疗痤疮抗过敏的组合物制剂及制备工艺 - Google Patents
一种治疗痤疮抗过敏的组合物制剂及制备工艺 Download PDFInfo
- Publication number
- CN113332215A CN113332215A CN202110837915.8A CN202110837915A CN113332215A CN 113332215 A CN113332215 A CN 113332215A CN 202110837915 A CN202110837915 A CN 202110837915A CN 113332215 A CN113332215 A CN 113332215A
- Authority
- CN
- China
- Prior art keywords
- extract
- raw material
- combined raw
- combined
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 206010000496 acne Diseases 0.000 title claims abstract description 24
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 21
- 206010020751 Hypersensitivity Diseases 0.000 title claims description 12
- 208000026935 allergic disease Diseases 0.000 title claims description 12
- 230000007815 allergy Effects 0.000 title claims description 12
- 239000000284 extract Substances 0.000 claims abstract description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 15
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 10
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- -1 PEG-100 stearate Chemical compound 0.000 claims abstract description 9
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 7
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 7
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 7
- 244000197580 Poria cocos Species 0.000 claims abstract description 7
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 7
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 7
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 7
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 7
- 235000020691 dandelion extract Nutrition 0.000 claims abstract description 7
- 229940067866 dandelion extract Drugs 0.000 claims abstract description 7
- 229940105902 mint extract Drugs 0.000 claims abstract description 7
- 229940064064 purslane extract Drugs 0.000 claims abstract description 7
- 229940119485 safflower extract Drugs 0.000 claims abstract description 7
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims abstract description 7
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 5
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 5
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 5
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 5
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 claims abstract description 5
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims abstract description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 5
- 229960000458 allantoin Drugs 0.000 claims abstract description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 5
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 5
- KIUVQMGRTDPAFR-UHFFFAOYSA-N benzoic acid 2-hydroxy-2-phenylpropanamide Chemical compound C(C1=CC=CC=C1)(=O)O.OC(C(=O)N)(C)C1=CC=CC=C1 KIUVQMGRTDPAFR-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960003237 betaine Drugs 0.000 claims abstract description 5
- 229940036350 bisabolol Drugs 0.000 claims abstract description 5
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 5
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940073669 ceteareth 20 Drugs 0.000 claims abstract description 5
- 229940081733 cetearyl alcohol Drugs 0.000 claims abstract description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 5
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000011187 glycerol Nutrition 0.000 claims abstract description 5
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims abstract description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940100554 isononyl isononanoate Drugs 0.000 claims abstract description 5
- 229940031674 laureth-7 Drugs 0.000 claims abstract description 5
- 229940041616 menthol Drugs 0.000 claims abstract description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940100460 peg-100 stearate Drugs 0.000 claims abstract description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 5
- 229920002401 polyacrylamide Polymers 0.000 claims abstract description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 5
- 229940032094 squalane Drugs 0.000 claims abstract description 5
- 229960001295 tocopherol Drugs 0.000 claims abstract description 5
- 229930003799 tocopherol Natural products 0.000 claims abstract description 5
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 5
- 239000011732 tocopherol Substances 0.000 claims abstract description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 5
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 5
- 239000000230 xanthan gum Substances 0.000 claims abstract description 5
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 5
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 5
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 claims abstract description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 5
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims abstract description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 4
- 229940114926 stearate Drugs 0.000 claims abstract description 4
- 229940074410 trehalose Drugs 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims description 122
- 230000001804 emulsifying effect Effects 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 28
- 235000019198 oils Nutrition 0.000 claims description 15
- 238000005086 pumping Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 238000000265 homogenisation Methods 0.000 claims description 6
- 238000009924 canning Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 241000428811 Alternanthera Species 0.000 claims description 3
- 241000526900 Camellia oleifera Species 0.000 claims description 3
- 230000003255 anti-acne Effects 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 239000001198 melaleuca alternifolia leaf oil Substances 0.000 abstract description 2
- 240000001548 Camellia japonica Species 0.000 abstract 1
- 229920001661 Chitosan Polymers 0.000 abstract 1
- 235000018597 common camellia Nutrition 0.000 abstract 1
- 229960004063 propylene glycol Drugs 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000125175 Angelica Species 0.000 description 1
- 235000005593 Camellia sinensis f parvifolia Nutrition 0.000 description 1
- 244000041840 Camellia sinensis f. parvifolia Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗痤疮抗过敏的组合物制剂,由鲸蜡硬脂醇聚醚‑20硬脂酸酯、PEG‑100硬脂酸酯、鲸蜡硬脂醇、碳酸二辛酯、角鲨烷、生育酚、异壬酸异壬酯、油茶籽油、红没药醇、姜根提取物、聚二甲基硅氧烷、水、甘油聚醚‑26、甘油、EDTA二钠、尿囊素、黄原胶、透明质酸钠、烟酰胺、海藻糖、甜菜碱、1,2‑己二醇、对羟基苯乙酮、丁二醇、羟苯基丙酰胺苯甲酸、连翘提取物、茯苓提取物、忍冬提取物、红花提取物、丹参提取物、蒙古黄芪提取物、当归提取物、川赤芍提取物、川芎提取物、蒲公英提取物、马齿苋提取物、薄荷提取物、聚丙烯酰胺、C13‑14异链烷烃、月桂醇聚醚‑7、丙二醇、薄荷脑、互生叶白千层叶油组成;采用天然植物的提取物配伍,治疗痤疮效果明显。
Description
技术领域
本发明涉及化妆品技术领域,具体涉及一种治疗痤疮抗过敏的组合物制剂及制备工艺。
背景技术
痤疮,或称粉刺,是青春期男女较普遍存在的皮肤疾患之一,主要发生与面部、前胸和上背部等皮脂腺密集、皮脂分泌旺盛的部位,临床表现为白头粉刺、黑头粉刺和炎性丘疹,严重可出现脓疱、结节和囊肿,有些人治愈后还会留下疤痕、色素沉着。因此,它不仅是一种皮肤烦恼,还在社交、心理、情绪方面对患者有不良影响。
随着人们生活水平的提高以及对自身健康和美的追求,现代人越来越注重对面部肌肤的护理和保养。如何治疗痤疮,提高对外界环境刺激的抵御性,是目前行业内关注的重点。
发明内容
本发明的目的就在于解决上述问题,而提供一种治疗痤疮抗过敏的组合物制剂及制备工艺。
本发明通过以下技术方案来实现上述目的,一种治疗痤疮抗过敏的组合物制剂,由多组组合原料加工而成,其中,包括:
组合原料一,所述组合原料一由鲸蜡硬脂醇聚醚-20硬脂酸酯、PEG-100硬脂酸酯、鲸蜡硬脂醇、碳酸二辛酯、角鲨烷、生育酚、异壬酸异壬酯、油茶籽油、红没药醇、姜根提取物、聚二甲基硅氧烷组成;
组合原料二,所述组合原料二由水、甘油聚醚-26、甘油、EDTA二钠、尿囊素组成;
组合原料三,所述组合原料三由黄原胶、透明质酸钠组成;
组合原料四,所述组合原料四由烟酰胺、海藻糖、甜菜碱组成;
组合原料五,所述组合原料五由1,2-己二醇、对羟基苯乙酮组成;
组合原料六,所述组合原料六由丁二醇、1,2-戊二醇、羟苯基丙酰胺苯甲酸、水、连翘提取物、茯苓提取物、忍冬提取物、红花提取物、丹参提取物、蒙古黄芪提取物、当归提取物、川赤芍提取物、川芎提取物、蒲公英提取物、马齿苋提取物、薄荷提取物组成;
组合原料七,所述组合原料七由聚丙烯酰胺、C13-14 异链烷烃、月桂醇聚醚-7组成;
组合原料八,所述组合原料八由丙二醇、薄荷脑、互生叶白千层叶油组成。
优选的,多组所述组合原料的质量分数比为:组合原料一的质量份数为:12-13.2、组合原料二的质量份数为:31-32.5、组合原料三的质量份数为:0.2-0.31、组合原料四的质量份数为:2.2-2.8、组合原料五的质量份数为:0.8-1.2、组合原料六的质量份数为:50.1-51.2、组合原料七的质量份数为:0.6-1.1、组合原料八的质量份数为:0.8-1.25。
一种治疗痤疮抗过敏的组合物制剂生产工艺,包括以下步骤:
步骤S1,设置生产设备,所述生产设备包括油相锅、水相锅、容器、乳化锅、灌装机、包装机、喷码机、收膜装置;
步骤S2,将组合原料一加入油相锅中,进行搅拌,升温至80℃;
步骤S3,将组合原料二加入水相锅中,进行搅拌,升温至75℃-80℃;
步骤S4,将组合原料三放入容器内进行溶解;
步骤S5,将水相锅中的组合原料二抽入乳化锅中,再将容器内溶解后的组合原料三加入乳化锅中,将组合原料五加入乳化锅中,开启高速均质;
步骤S6,均质1-5min之后,观察原料无颗粒后,乳化锅进行抽真空,将油相锅中组合原料一抽入乳化锅中,再将组合原料七抽入乳化锅中,进行搅拌,温度升至75℃-80℃,开启高速均质,均质1-5min之后,进行恒温搅拌,恒温时间为20-30min;
步骤S7,恒温结束,加入组合原料四,开始降温;
步骤S8,当温度降至60℃时,加入组合原料六;
步骤S9,当温度降至48℃,加入组合原料八;
步骤S10,当温度降至35℃以下时,抽样进行检测;
步骤S11,出料,静置24h后罐装,罐装后进行包装。
优选的,步骤S2中,搅拌速度为3750r/min。
优选的,步骤S3中,搅拌速度为3750r/min。
优选的,步骤S6中,抽真空范围为0.035~0.045MPa,搅拌转速为15~25r/min,均质为25~30r/min。
本发明的有益效果是:
本发明治疗痤疮抗过敏的组合物制剂,采用天然植物的提取物配伍,连翘提取物、茯苓提取物、忍冬提取物、红花提取物、丹参提取物、蒙古黄芪提取物、当归提取物、川赤芍提取物、川芎提取物、蒲公英提取物、马齿苋提取物、薄荷提取物组合,治疗痤疮效果好,见效快,不留疤痕,对于各种原因引起的痤疮具有良好的治疗效果好。
附图说明
图1为本发明中多功能板材的结构示意图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
具体实施例1:
本实施例中一种治疗痤疮抗过敏的组合物制剂,由多组组合原料加工而成,其中,包括:
组合原料一,所述组合原料一由鲸蜡硬脂醇聚醚-20硬脂酸酯、PEG-100硬脂酸酯、鲸蜡硬脂醇、碳酸二辛酯、角鲨烷、生育酚、异壬酸异壬酯、油茶籽油、红没药醇、姜根提取物、聚二甲基硅氧烷组成;
组合原料二,所述组合原料二由水、甘油聚醚-26、甘油、EDTA二钠、尿囊素组成;
组合原料三,所述组合原料三由黄原胶、透明质酸钠组成;
组合原料四,所述组合原料四由烟酰胺、海藻糖、甜菜碱组成;
组合原料五,所述组合原料五由1,2-己二醇、对羟基苯乙酮组成;
组合原料六,所述组合原料六由丁二醇、1,2-戊二醇、羟苯基丙酰胺苯甲酸、水、连翘提取物、茯苓提取物、忍冬提取物、红花提取物、丹参提取物、蒙古黄芪提取物、当归提取物、川赤芍提取物、川芎提取物、蒲公英提取物、马齿苋提取物、薄荷提取物组成;
组合原料七,所述组合原料七由聚丙烯酰胺、C13-14 异链烷烃、月桂醇聚醚-7组成;
组合原料八,所述组合原料八由丙二醇、薄荷脑、互生叶白千层叶油组成;
多组所述组合原料的质量分数比为:组合原料一的质量份数为:12-13.2、组合原料二的质量份数为:31-32.5、组合原料三的质量份数为:0.2-0.31、组合原料四的质量份数为:2.2-2.8、组合原料五的质量份数为:0.8-1.2、组合原料六的质量份数为:50.1-51.2、组合原料七的质量份数为:0.6-1.1、组合原料八的质量份数为:0.8-1.25。
如图1所示:
本实施例中,一种治疗痤疮抗过敏的组合物制剂制备工艺,包括以下步骤:
步骤S1,设置生产设备,所述生产设备包括油相锅、水相锅、容器、乳化锅、灌装机、包装机、喷码机、收膜装置;
步骤S2,将组合原料一加入油相锅中,进行搅拌,升温至80℃,其中,搅拌速度为3750r/min;
步骤S3,将组合原料二加入水相锅中,进行搅拌,升温至75℃-80℃,其中,搅拌速度为3750r/min;
步骤S4,将组合原料三放入容器内进行溶解;
步骤S6,将水相锅中的组合原料二抽入乳化锅中,再将容器内溶解后的组合原料三加入乳化锅中,将组合原料五加入乳化锅中,开启高速均质;
步骤S6,均质1-5min之后,观察原料无颗粒后,乳化锅进行抽真空,将油相锅中组合原料一抽入乳化锅中,再将组合原料七抽入乳化锅中,进行搅拌,温度升至75℃-80℃,开启高速均质,均质1-5min之后,进行恒温搅拌,恒温时间为20-30min,其中,抽真空范围为0.035~0.045MPa,搅拌转速为15~25r/min,均质为25~30r/min;
步骤S7,恒温结束,加入组合原料四,开始降温;
步骤S8,当温度降至60℃时,加入组合原料六;
步骤S9,当温度降至48℃,加入组合原料八;
步骤S10,当温度降至35℃以下时,抽样进行检测;
步骤S11,出料,静置24h后罐装,罐装后进行包装。
具体实施例2:
本实施例中一种治疗痤疮抗过敏的组合物制剂,由多组组合原料加工而成,其中,质量分数比为:
组合原料一的质量分数为12.6、组合原料二的质量分数为31.25、组合原料三的质量分数为0.25、组合原料四的质量分数为2.5、组合原料五的质量分数为1、组合原料六的质量分数为50.5、组合原料七的质量分数为0.8、组合原料八的质量分数为1.1;
组合原料一中,由鲸蜡硬脂醇聚醚-20硬脂酸酯的质量分数为1、PEG-100硬脂酸酯的质量分数为1.5、鲸蜡硬脂醇的质量分数为1、碳酸二辛酯的质量分数为2、角鲨烷的质量分数为2、生育酚的质量分数为0.5、异壬酸异壬酯的质量分数为1、油茶籽油的质量分数为0.5、红没药醇与姜根提取物的质量分数为0.1、聚二甲基硅氧烷的质量分数为3;
组合原料二中,水的质量分数为25.9、甘油聚醚-26的质量分数为3、甘油的质量分数为2、EDTA二钠的质量分数为0.05、尿囊素的质量分数为0.3;
组合原料三中,黄原胶的质量分数为0.15、透明质酸钠的质量分数为0.1;
组合原料四中,烟酰胺的质量分数为1、海藻糖的质量分数为0.5、甜菜碱的质量分数为1;
组合原料五中,1,2-己二醇的质量分数为0.5、对羟基苯乙酮的质量分数为0.5;
组合原料六中,丁二醇、1,2-戊二醇及羟苯基丙酰胺苯甲酸的质量分数为0.5,水、连翘提取物、茯苓提取物、忍冬提取物、红花提取物、丹参提取物、蒙古黄芪提取物、当归提取物、川赤芍提取物、川芎提取物、蒲公英提取物、马齿苋提取物及薄荷提取物的质量分数为50;
组合原料七中,聚丙烯酰胺、C13-14 异链烷烃及月桂醇聚醚-7的质量分数为0.8;
组合原料八中,丙二醇的质量分数为1、薄荷脑0.05、互生叶白千层叶油0.05。
如图1所示:
本实施例中,一种治疗痤疮抗过敏的组合物制剂制备工艺,包括以下步骤:
步骤S1,设置生产设备,所述生产设备包括油相锅、水相锅、容器、乳化锅、灌装机、包装机、喷码机、收膜装置;
步骤S2,将组合原料一加入油相锅中,进行搅拌,升温至80℃,其中,搅拌速度为3750r/min;
步骤S3,将组合原料二加入水相锅中,进行搅拌,升温至75℃-80℃,其中,搅拌速度为3750r/min;
步骤S4,将组合原料三放入容器内进行溶解;
步骤S6,将水相锅中的组合原料二抽入乳化锅中,再将容器内溶解后的组合原料三加入乳化锅中,将组合原料五加入乳化锅中,开启高速均质;
步骤S6,均质1-5min之后,观察原料无颗粒后,乳化锅进行抽真空,将油相锅中组合原料一抽入乳化锅中,再将组合原料七抽入乳化锅中,进行搅拌,温度升至75℃-80℃,开启高速均质,均质1-5min之后,进行恒温搅拌,恒温时间为20-30min,其中,抽真空范围为0.035~0.045MPa,搅拌转速为15~25r/min,均质为25~30r/min;
步骤S7,恒温结束,加入组合原料四,开始降温;
步骤S8,当温度降至60℃时,加入组合原料六;
步骤S9,当温度降至48℃,加入组合原料八;
步骤S10,当温度降至35℃以下时,抽样进行检测;
步骤S11,出料,静置24h后罐装,罐装后进行包装。
本发明一种治疗痤疮抗过敏的组合物制剂,采用天然植物的提取物配伍,连翘提取物、茯苓提取物、忍冬提取物、红花提取物、丹参提取物、蒙古黄芪提取物、当归提取物、川赤芍提取物、川芎提取物、蒲公英提取物、马齿苋提取物、薄荷提取物组合,治疗痤疮效果好,见效快,不留疤痕,对于各种原因引起的痤疮具有良好的治疗效果好。
于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。不应将权利要求中的任何附图标记视为限制所涉及的权利要求。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (6)
1.一种治疗痤疮抗过敏的组合物制剂,其特征在于,由多组组合原料加工而成,其中,包括:
组合原料一,所述组合原料一由鲸蜡硬脂醇聚醚-20硬脂酸酯、PEG-100硬脂酸酯、鲸蜡硬脂醇、碳酸二辛酯、角鲨烷、生育酚、异壬酸异壬酯、油茶籽油、红没药醇、姜根提取物、聚二甲基硅氧烷组成;
组合原料二,所述组合原料二由水、甘油聚醚-26、甘油、EDTA二钠、尿囊素组成;
组合原料三,所述组合原料三由黄原胶、透明质酸钠组成;
组合原料四,所述组合原料四由烟酰胺、海藻糖、甜菜碱组成;
组合原料五,所述组合原料五由1,2-己二醇、对羟基苯乙酮组成;
组合原料六,所述组合原料六由丁二醇、1,2-戊二醇、羟苯基丙酰胺苯甲酸、水、连翘提取物、茯苓提取物、忍冬提取物、红花提取物、丹参提取物、蒙古黄芪提取物、当归提取物、川赤芍提取物、川芎提取物、蒲公英提取物、马齿苋提取物、薄荷提取物组成;
组合原料七,所述组合原料七由聚丙烯酰胺、C13-14异链烷烃、月桂醇聚醚-7组成;
组合原料八,所述组合原料八由丙二醇、薄荷脑、互生叶白千层叶油组成。
2.根据权利要求1所述的一种治疗痤疮抗过敏的组合物制剂,其特征在于:多组所述组合原料的质量分数比为:组合原料一的质量份数为:12-13.2、组合原料二的质量份数为:31-32.5、组合原料三的质量份数为:0.2-0.31、组合原料四的质量份数为:、组合原料五的质量份数为:、组合原料六的质量份数为:50.1-51.2、组合原料七的质量份数为:0.6-1.1、组合原料八的质量份数为:0.8-1.25。
3.一种治疗痤疮抗过敏的组合物制剂制备工艺,其特征在于,包括以下步骤:
步骤S1,设置生产设备,所述生产设备包括油相锅、水相锅、容器、乳化锅、灌装机、包装机、喷码机、收膜装置;
步骤S2,将组合原料一加入油相锅中,进行搅拌,升温至80℃;
步骤S3,将组合原料二加入水相锅中,进行搅拌,升温至75℃-80℃;
步骤S4,将组合原料三放入容器内进行溶解;
步骤S5,将水相锅中的组合原料二抽入乳化锅中,再将容器内溶解后的组合原料三加入乳化锅中,将组合原料五加入乳化锅中,开启高速均质;
步骤S6,均质1-5min之后,观察原料无颗粒后,乳化锅进行抽真空,将油相锅中组合原料一抽入乳化锅中,再将组合原料七抽入乳化锅中,进行搅拌,温度升至75℃-80℃,开启高速均质,均质1-5min之后,进行恒温搅拌,恒温时间为20-30min;
步骤S7,恒温结束,加入组合原料四,开始降温;
步骤S8,当温度降至60℃时,加入组合原料六;
步骤S9,当温度降至48℃,加入组合原料八;
步骤S10,当温度降至35℃以下时,抽样进行检测;
步骤S11,出料,静置24h后罐装,罐装后进行包装。
4.根据权利要求3所述的一种治疗痤疮抗过敏的组合物制剂制备工艺,其特征在于:步骤S2中,搅拌速度为3750r/min。
5.根据权利要求3所述的一种治疗痤疮抗过敏的组合物制剂制备工艺,其特征在于:步骤S3中,搅拌速度为3750r/min。
6.根据权利要求3所述的一种治疗痤疮抗过敏的组合物制剂制备工艺,其特征在于:步骤S6中,抽真空范围为0.035~0.045MPa,搅拌转速为15~25r/min,均质为25~30r/min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110837915.8A CN113332215A (zh) | 2021-07-23 | 2021-07-23 | 一种治疗痤疮抗过敏的组合物制剂及制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110837915.8A CN113332215A (zh) | 2021-07-23 | 2021-07-23 | 一种治疗痤疮抗过敏的组合物制剂及制备工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113332215A true CN113332215A (zh) | 2021-09-03 |
Family
ID=77480315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110837915.8A Pending CN113332215A (zh) | 2021-07-23 | 2021-07-23 | 一种治疗痤疮抗过敏的组合物制剂及制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113332215A (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050084473A1 (en) * | 2003-10-20 | 2005-04-21 | William Lee | Treatment of acne by topical herbal extract solution |
CN106963695A (zh) * | 2017-05-17 | 2017-07-21 | 覃兴 | 一种苦黄净痘凝露 |
CN108392620A (zh) * | 2018-05-28 | 2018-08-14 | 四川省中医药科学院 | 一种治疗皮炎的联合用康养产品及其用途 |
CN108543044A (zh) * | 2018-05-28 | 2018-09-18 | 四川省中医药科学院中医研究所 | 一种治疗痤疮的联合用药物及其用途 |
CN108938513A (zh) * | 2017-10-25 | 2018-12-07 | 游云利 | 一种量子清肤祛痘美颜霜及其制备方法 |
CN109276535A (zh) * | 2018-12-04 | 2019-01-29 | 天津尚美化妆品有限公司 | 含中药成分的蜂蜜美白面膜 |
CN109730954A (zh) * | 2019-02-23 | 2019-05-10 | 中美杜克(广州)护肤研究中心(普通合伙) | 具有镇敏、舒缓、修护、改善皮脂膜作用的护肤品及其制备方法 |
CN109820780A (zh) * | 2019-03-13 | 2019-05-31 | 广州科恩生物技术有限公司 | 一种治疗痤疮洁面啫喱及其制备方法 |
CN110882196A (zh) * | 2019-12-26 | 2020-03-17 | 北京极暖网络科技有限公司 | 舒缓活力霜及其制备方法 |
CN112315882A (zh) * | 2020-11-23 | 2021-02-05 | 山东福瑞达生物工程有限公司 | 一种舒缓修护保湿面霜及其制备方法 |
CN112641670A (zh) * | 2020-12-31 | 2021-04-13 | 彭氏(惠州)实业发展有限公司 | 保湿精华乳及其制备方法 |
-
2021
- 2021-07-23 CN CN202110837915.8A patent/CN113332215A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050084473A1 (en) * | 2003-10-20 | 2005-04-21 | William Lee | Treatment of acne by topical herbal extract solution |
CN106963695A (zh) * | 2017-05-17 | 2017-07-21 | 覃兴 | 一种苦黄净痘凝露 |
CN108938513A (zh) * | 2017-10-25 | 2018-12-07 | 游云利 | 一种量子清肤祛痘美颜霜及其制备方法 |
CN108392620A (zh) * | 2018-05-28 | 2018-08-14 | 四川省中医药科学院 | 一种治疗皮炎的联合用康养产品及其用途 |
CN108543044A (zh) * | 2018-05-28 | 2018-09-18 | 四川省中医药科学院中医研究所 | 一种治疗痤疮的联合用药物及其用途 |
CN109276535A (zh) * | 2018-12-04 | 2019-01-29 | 天津尚美化妆品有限公司 | 含中药成分的蜂蜜美白面膜 |
CN109730954A (zh) * | 2019-02-23 | 2019-05-10 | 中美杜克(广州)护肤研究中心(普通合伙) | 具有镇敏、舒缓、修护、改善皮脂膜作用的护肤品及其制备方法 |
CN109820780A (zh) * | 2019-03-13 | 2019-05-31 | 广州科恩生物技术有限公司 | 一种治疗痤疮洁面啫喱及其制备方法 |
CN110882196A (zh) * | 2019-12-26 | 2020-03-17 | 北京极暖网络科技有限公司 | 舒缓活力霜及其制备方法 |
CN112315882A (zh) * | 2020-11-23 | 2021-02-05 | 山东福瑞达生物工程有限公司 | 一种舒缓修护保湿面霜及其制备方法 |
CN112641670A (zh) * | 2020-12-31 | 2021-04-13 | 彭氏(惠州)实业发展有限公司 | 保湿精华乳及其制备方法 |
Non-Patent Citations (2)
Title |
---|
国产非特殊用途化妆品备案服务平台: "卓芝缘亮肤润颜草本套-亮肤润颜草本精华液", 《国产非特殊用途化妆品备案服务HTTP://FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=20210226173017GQV36&NID=20210226173017GQV36》 * |
解玉 等: "中药面膜治疗寻常型痤疮66例临床观察", 《现代中西医结合杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101254156B (zh) | 一种化妆品组合物及其制备化妆品的用途 | |
CN102151241B (zh) | 一种含天然植物提取物的牙膏及其制备方法 | |
CN108938513B (zh) | 一种清肤祛痘美颜霜及其制备方法 | |
CN105997657A (zh) | 一种保湿美白中药组合物 | |
CN112516034A (zh) | 一种植物祛痘剂及其制备方法和用途 | |
CN110433122A (zh) | 一种组合物及其在制备淡斑美白的护肤品中的应用 | |
CN114028295A (zh) | 一种抑菌止痒褪红祛痘修护组合物及其制备方法和应用 | |
CN104337712A (zh) | 一种含有广玉兰种子油的抗皱、祛皱用保养品 | |
CN111388610A (zh) | 一种预防牙龈萎缩和/或治疗牙龈炎的中药组合物 | |
CN107669617A (zh) | 天然祛皱嫩肤化妆品 | |
CN101766557A (zh) | 一种美白化妆品组合物 | |
CN111000759A (zh) | 一种佛手柑精油修护霜及制备方法 | |
CN105362197B (zh) | 一种含中草药提取物的祛痘保湿面膜粉及其制备方法 | |
CN112043661B (zh) | 一种美白芦荟胶及其制备方法 | |
CN107007508A (zh) | 一种美白补水面膜 | |
CN109966193A (zh) | 一种改善皮肤功能的组合物及其制备方法和应用 | |
CN105534750A (zh) | 一种祛痘面膜 | |
CN115607510A (zh) | 一种高浓度齐墩果酸纳米乳组合物及制备方法 | |
CN113332215A (zh) | 一种治疗痤疮抗过敏的组合物制剂及制备工艺 | |
CN104840380A (zh) | 一种天然物质组合物及其在美白化妆品中的应用 | |
CN104666161A (zh) | 一种中药美白祛斑膏 | |
CN101467946A (zh) | 一种养颜修复霜 | |
CN103860436B (zh) | 含有五味子提取物的化妆品组合物及美白滋养霜 | |
CN104958196A (zh) | 金花茶叶提取物的应用、美白护肤组合物及其制备方法 | |
CN110013459A (zh) | 一种含中药姜黄的护肤组合物及具有减皱功效的护肤品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210903 |
|
RJ01 | Rejection of invention patent application after publication |